COVID-19: Impact in endothelial function and therapy with Mesenchymal Stromal Cells

Carla  Longo de Freitas; Priscilla Yuri  Okochi Alves da silva; Maria do Carmo  Pinho Franco; Danilo Candido  de Almeida

doi:10.54502/msuceva.v1n1a2

Autores/as

Carla Longo de Freitas University of São Paulo, São Paulo, Brazil https://orcid.org/0000-0002-7218-8597
Priscilla Yuri Okochi Alves da silva Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, Brazil https://orcid.org/0000-0001-7784-0145
Maria do Carmo Pinho Franco Division of Nephrology, Medicine Department, School of Medicine, Federal University of São Paulo, São Paulo, Brazil https://orcid.org/0000-0003-0604-7689
Danilo Candido de Almeida Division of Nephrology, Medicine Department, School of Medicine, Federal University of São Paulo, São Paulo, Brazil https://orcid.org/0000-0003-3661-2124

DOI:

https://doi.org/10.54502/msuceva.v1n1a2

Palabras clave:

COVID-19 pathophysiology, Endothelial disfunction, Immune cells, Mesenchymal Stromal Cells, Pathogenesis

Resumen

The new pandemic of SARS-CoV-2 Betacoronavirus, has spread worldwide, and infected millions of individuals causing the disease denominated of COVID-19. Further on flu symptoms, due to the high tropism of virus, has most been observed in the COVID-19 pathophysiology: acute heart failure, thromboembolism events, acute renal failure, neurological and liver damage, and multiple organ failure, with special attention to endothelial disfunction. Hence, elucidate whether virus target the endothelium is a crucial step to understand COVID-19 pathogenesis. However, the permissiveness of blood vessels during SARS-CoV-2 infection remains unclear, but regardless endothelial infection, the vascular disfunction may occurred in response to molecular inflammatory signaling triggered by immune cells that attempt to limit infection. Thus, alternative therapies using mesenchymal stromal cells (MSCs) can change this scenario and help critically ill patients. In this reflection, we attempt to discuss COVID-19 pathophysiology with impact in endothelial function and explore the applicability of MSC-based therapies as alternative treatment.

Descargas

Los datos de descargas todavía no están disponibles.

Métricas

Cargando métricas ...

Biografía del autor/a

Carla Longo de Freitas, University of São Paulo, São Paulo, Brazil

Received his PhD degree in Immunology from Federal University of São Paulo, São Paulo, Brazil. Currently, she is pursuing a postdoctoral stay in the Department of Medicine, Discipline of Nephrology, Federal University of São Paulo-Escola Paulista de Medicina (UNIFESP/EPM). She aims to investigate the impact of COVID-19 on the kidneys and endothelium, studying the in vitro infection by SARS-CoV-2 in renal and endothelial cells; and the therapeutic potential of Mesenchymal Stem Cells.

Priscilla Yuri Okochi Alves da silva, Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, Brazil

She is a doctoral student in the Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, Brazil (UNIFESP/Brazil). Her research line is defined as “use of organ-on-chip to study the endothelium-kidney axis in SARSCoV-2 infection; and therapeutic strategies with Mesenchymal Stem Cells.” Graduated in Biomedicine at the University Center of Faculdades Metropolitanas Unidas (FMU/Brazil), completed in 2013. Areas of expertise: medicine, biological sciences, immunology and microbiology.

Maria do Carmo Pinho Franco, Division of Nephrology, Medicine Department, School of Medicine, Federal University of São Paulo, São Paulo, Brazil

Studied Biomedicine and she started his research career at the Department of Pharmacology at the University of São Paulo, Brazil, where she also accomplished his doctoral thesis. In the following years she worked in the field of vascular biology with the focus on fetal programming. The main topics of her research group are fetal programming of cardiovascular diseases and exploration of novel targets involved in the development of cardiometabolic disease focusing on endothelial function as well as biomarker research.

Danilo Candido de Almeida, Division of Nephrology, Medicine Department, School of Medicine, Federal University of São Paulo, São Paulo, Brazil

Is Doctor in Biomedical Sciences (Medicine-Nephrology) from the Federal University of São Paulo-UNIFESP, Brazil with Post-doctorate at the Federal University of São Paulo (Nephrology), University of São Paulo, Brazil (Immunology) and at the Helmholtz-Institute for Biomedical Engineering - RWTH Aachen University (Aachen, Germany). He is currently an Associate Professor and Advisor at the Department of Medicine, Discipline of Nephrology at the Federal University of São Paulo, Brazil. Dr Almeida has experience in Cell Biology, Molecular Biology and Genetics, with an emphasis on the function of micromolecules. Main topics are as follows: Mesenchymal stem cell, cell therapy, large-scale data analysis and experimental model of inflammatory and renal lesions.

Citas

Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579. https://doi.org/10.1038/s41586-020-2012-7.

Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, et al. A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong. New England Journal of Medicine 2003;348. https://doi.org/10.1056/NEJMoa030666.

Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong. New England Journal of Medicine 2003;348. https://doi.org/10.1056/NEJMoa030685.

Cheng VCC, Lau SKP, Woo PCY, Yuen KY. Severe Acute Respiratory Syndrome Coronavirus as an Agent of Emerging and Reemerging Infection. Clinical Microbiology Reviews 2007;20. https://doi.org/10.1128/CMR.00023-07.

World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard. WHO Covid-19 Homepage 2021. https://covid19.who.int/.

Mao R, Qiu Y, He J-S, Tan J-Y, Li X-H, Liang J, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology 2020;5. https://doi.org/10.1016/S2468-1253(20)30126-6.

Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. The Lancet Haematology 2020;7. https://doi.org/10.1016/S2352-3026(20)30145-9.

Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, et al. Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection. JAMA 2020;323. https://doi.org/10.1001/jama.2020.6771.

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Internal Medicine 2020;180. https://doi.org/10.1001/jamainternmed.2020.0994.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020;395. https://doi.org/10.1016/S0140-6736(20)30183-5.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine 2020;382. https://doi.org/10.1056/NEJMoa2002032.

Chen Y-T, Shao S-C, Hsu C-K, Wu I-W, Hung M-J, Chen Y-C. Incidence of acute kidney injury in COVID-19 infection: a systematic review and meta-analysis. Critical Care 2020;24. https://doi.org/10.1186/s13054-020-03009-y.

de Almeida DC, Franco M do CP, dos Santos DRP, Santos MC, Maltoni IS, Mascotte F, et al. Acute kidney injury: Incidence, risk factors, and outcomes in severe COVID-19 patients. PLOS ONE 2021;16. https://doi.org/10.1371/journal.pone.0251048.

Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine 2020;8. https://doi.org/10.1016/S2213-2600(20)30079-5.

Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020;323. https://doi.org/10.1001/jama.2020.5394.

Lam TT-Y, Jia N, Zhang Y-W, Shum MH-H, Jiang J-F, Zhu H-C, et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature 2020;583. https://doi.org/10.1038/s41586-020-2169-0.

Glowacka I, Bertram S, Muller MA, Allen P, Soilleux E, Pfefferle S, et al. Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response. Journal of Virology 2011;85. https://doi.org/10.1128/JVI.02232-10.

Hoffmann M, Kleine-Weber H, Schroeder S, KrŸger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020;181. https://doi.org/10.1016/j.cell.2020.02.052.

Fosse JH, Haraldsen G, Falk K, Edelmann R. Endothelial Cells in Emerging Viral Infections. Frontiers in Cardiovascular Medicine 2021;8. https://doi.org/10.3389/fcvm.2021.619690.

Liu F, Han K, Blair R, Kenst K, Qin Z, Upcin B, et al. SARSCoV-2 Infects Endothelial Cells In Vivo and In Vitro. Frontiers in Cellular and Infection Microbiology 2021;11. https://doi.org/10.3389/fcimb.2021.701278.

Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19. New England Journal of Medicine 2020;382. https://doi.org/10.1056/NEJMoa2006923.

Fosb, l EL, Butt JH, ¯stergaard L, Andersson C, Selmer C, Kragholm K, et al. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. JAMA 2020;324. https://doi.org/10.1001/jama.2020.11301.

Nassiri SM, Rahbarghazi R. Interactions of Mesenchymal Stem Cells with Endothelial Cells. Stem Cells and Development 2014;23. https://doi.org/10.1089/scd.2013.0419.

Saeedi P, Halabian R, Imani Fooladi AA. A revealing review of mesenchymal stem cells therapy, clinical perspectives and modification strategies. Stem Cell Investigation 2019;6:1–8. https://doi.org/10.21037/sci.2019.08.11.

Clinical Trials.gov. Federally-funded clinical studies related to COVID-19. NIH US National Library of Medicine 2021. https://clinicaltrials.gov/.

Durand N, Mallea J, Zubair AC. Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure. Npj Regenerative Medicine 2020;5. https://doi.org/10.1038/s41536-020-00105-z